Company Overview

Race Oncology (ASX: RAC) is an Australian (ASX-listed) clinical stage, biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Our focus is on addressing the high unmet need of cancer patients for better and less damaging treatments that leverage the unique activity of our lead drug, RC220 bisantrene.

RC220 is a propriety reformulated version of bisantrene, designed for improved safety and clinical utility. Bisantrene is a small molecule chemotherapeutic with a rich clinical history of demonstrated anticancer activity with lower rates of cardiotoxicity compared to the widely used anthracyclines, such as doxorubicin.

Originally developed in the 1970s and 1980’s as an alternative to the cardiotoxic anthracycline chemotherapeutic, bisantrene has been evaluated in over 50 human clinical trials with more than 1,500 patients treated.

Race Oncology has discovered in a series of exciting preclinical studies that bisantrene is not only less cardiotoxic than current anthracyclines, but when used in combination with anthracyclines can protect the heart from anthracycline-induced damage while providing additional anticancer activity.

Race is advancing RC220 to address the high unmet needs of patients for better treatments across multiple oncology indications, with a clinical focus on anthracycline combinations with aim of protecting patient’s hearts from the permanent damage caused by chemotherapy while providing enhanced anticancer activity in a range of solid tumours.

In addition, Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity- associated protein), a known m⁶A RNA demethylase. Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies to be a driver of a diverse range of cancers.

Led by a highly experienced and passionate leadership team who are supported by a panel of expert advisors, Race Oncology’s business strategy has evolved to take advantage of recent clinical insights.